Oral Biologics Market

Oral Biologics Market, By Drug Class (Glucagon-like Peptide 1 (GLP-1) Receptor Agonist, Hormone, Recombinant Enzyme, Guanylate Cyclase-C Agonist, Somatostatin Analogue, Others), By Disease Indication (Diabetes, Hyperoxaluria, Acromegaly, Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC), Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism, and Others)), By Distribution channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Oral biologics refers to a category of medications that are biologically derived, like proteins or antinodies, and are administered orally (in the form of pills and capsules) rather than through injections. This segment has garnered significant attention and investment due to its potential to revolutionize the treatment landscape across various therapeutic areas. The potential applications of oral biologics span a wide range of therapeutic areas. Autoimmune disorders, including rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis, are among the prominent targets. Additionally, oral biologics hold promise for treating diabetes, cancer, and rare genetic diseases. This versatility has attracted attention from both pharmaceutical giants and innovative startups, fostering a competitive landscape that drives innovation and collaboration in the market. Further, patient convenience and technological advancements have positioned oral biologics as a promising alternative to traditional injectable biologics, which is expected to drive market growth in the forecast years.

Market Dynamics

The key market players are focused on the launch of new products in the market to expand their business globally, and this is expected to boost the growth of the market over the forecast period. For instance, in January 2022, Novo Nordisk, a global pharmaceutical company, launched the GLP-1 receptor analogue (GLP-1 RA) in an oral pill formulation for the treatment of diabetes. Before the launch of the GLP-1 receptor analogue (GLP-1 RA) oral pill, GLP-1 receptor analogue (GLP-1 RA) was only available in injection form. A GLP-1 RA has never before been created in an oral formulation. In order to prevent it from degrading in the stomach like other peptides do and to improve absorption, oral semaglutide is a co-formulation of GLP-1RA semaglutide and the absorption enhancer SNAC.

Key features of the study:

• This report provides an in-depth analysis of the global oral biologics market and provides market size (US$ Billion) and compound annual growth rate (CAGR) for the forecast period (2023–2030), considering 2022 as the base year It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global oral biologics market based on the following parameters– company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Novo Nordisk A/S, Biocon Limited, Oramed Pharmaceuticals, Inc., Rani Therapeutics, Entera Bio Ltd., AbbVie Inc., Enteris BioPharma, Inc., Chiasma, Inc. and Allena Pharmaceuticals, Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global oral biologics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global oral biologics market.

Oral Biologics Market Detailed Segmentation:

• By Drug Class:
• Glucagon-like Peptide 1 (GLP-1) Receptor Agonist
• Hormone
• Recombinant Enzyme
• Guanylate Cyclase-C Agonist
• Somatostatin Analogue
• Others
• By Disease Indication:
• Diabetes
• Hyperoxaluria
• Acromegaly
• Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)
• Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism, and Others)
• By Distribution channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• By Region:
• North America
• Latin America
• Europe
• Asia Pacific
• Middle East
• Africa
• Company Profiles
• Novo Nordisk A/S
• Biocon Limited
• Oramed Pharmaceuticals, Inc.
• Rani Therapeutics
• Entera Bio Ltd.
• AbbVie Inc.
• Enteris BioPharma, Inc.
• Chiasma, Inc.
• Allena Pharmaceuticals, Inc.